Lv1
18 积分 2023-10-21 加入
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
8个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
8个月前
已完结
The gut microbiota-bile acid axis: a crucial regulator of immune function and metabolic health
8个月前
已完结
High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysis
8个月前
已完结
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
10个月前
已完结
皖公网安备34019202002308
